Standardized incidence ratio (SIR) (95% CI) and excess absolute risk (EAR) (95% CI) for subsequent malignant neoplasms (SMN) at 25 years after primary cancer diagnosis
| . | Observed . | Expected . | SIR (95% CI) . | EAR (95% CI) per 10 000 person-years . |
|---|---|---|---|---|
| All SMNs | 28 | 3.451 | 8.1 (5.4 to 12.1) | 16.1 (10.0 to 25.0) |
| Sex | ||||
| Male | 13 | 1.559 | 8.3 (4.9 to 14.3) | 15.3 (8.1 to 27.7) |
| Female | 15 | 1.892 | 7.9 (4.4 to 14.2) | 16.8 (8.3 to 31.8) |
| Risk | ||||
| Low risk | 2 | 1.552 | 1.3 (0.2 to 9.1) | 0.7 (−1.9 to 18.7) |
| Intermediate risk | 3 | 0.815 | 3.7 (1.2 to 11.3) | 5.4 (0.4 to 20.9) |
| High risk | 22 | 0.787 | 28.0 (18.5 to 42.3) | 64.7 (42 to 99.0) |
| Age at diagnosis | ||||
| <1 | 3 | 1.430 | 2.1 (0.7 to 6.5) | 2.1 (−0.6 to 10.4) |
| 1-4 | 15 | 1.431 | 10.5 (6.2 to 17.8) | 21.3 (11.6 to 37.6) |
| 5-9 | 7 | 0.366 | 19.1 (8.5 to 43.2) | 62.1 (25.6 to 144.6) |
| ≥10 | 3 | 0.224 | 13.4 (3.6 to 50.3) | 87.7 (18.2 to 347.9) |
| SMN subtype | ||||
| Thyroid | 9 | 0.437 | 20.6 (9.5 to 44.5) | 5.6 (2.4 to 12.4) |
| Sarcoma | 7 | 0.367 | 19.1 (8.3 to 44.1) | 4.3 (1.7 to 10.4) |
| Acute myeloid leukemia | 2 | 0.090 | 22.3 (5.6 to 89.1) | 1.3 (0.3 to 5.2) |
| Other glial | 1 | 0.088 | 11.3 (1.6 to 80.3) | 0.6 (0 to 4.6) |
| Breast | 1 | 0.109 | 9.1 (1.3 to 65.7) | 0.6 (0 to 4.6) |
| Non-Hodgkin lymphoma | 1 | 0.232 | 4.3 (0.6 to 30.6) | 0.5 (−0.1 to 4.5) |
| Small intestine and colorectal | 1 | 0.094 | 10.6 (1.5 to 75.3) | 0.6 (0.0 to 4.6) |
| Other cancersa | 6 | 0.559 | 10.7 (4.8 to 23.9) | 3.6 (1.4 to 8.4) |
| . | Observed . | Expected . | SIR (95% CI) . | EAR (95% CI) per 10 000 person-years . |
|---|---|---|---|---|
| All SMNs | 28 | 3.451 | 8.1 (5.4 to 12.1) | 16.1 (10.0 to 25.0) |
| Sex | ||||
| Male | 13 | 1.559 | 8.3 (4.9 to 14.3) | 15.3 (8.1 to 27.7) |
| Female | 15 | 1.892 | 7.9 (4.4 to 14.2) | 16.8 (8.3 to 31.8) |
| Risk | ||||
| Low risk | 2 | 1.552 | 1.3 (0.2 to 9.1) | 0.7 (−1.9 to 18.7) |
| Intermediate risk | 3 | 0.815 | 3.7 (1.2 to 11.3) | 5.4 (0.4 to 20.9) |
| High risk | 22 | 0.787 | 28.0 (18.5 to 42.3) | 64.7 (42 to 99.0) |
| Age at diagnosis | ||||
| <1 | 3 | 1.430 | 2.1 (0.7 to 6.5) | 2.1 (−0.6 to 10.4) |
| 1-4 | 15 | 1.431 | 10.5 (6.2 to 17.8) | 21.3 (11.6 to 37.6) |
| 5-9 | 7 | 0.366 | 19.1 (8.5 to 43.2) | 62.1 (25.6 to 144.6) |
| ≥10 | 3 | 0.224 | 13.4 (3.6 to 50.3) | 87.7 (18.2 to 347.9) |
| SMN subtype | ||||
| Thyroid | 9 | 0.437 | 20.6 (9.5 to 44.5) | 5.6 (2.4 to 12.4) |
| Sarcoma | 7 | 0.367 | 19.1 (8.3 to 44.1) | 4.3 (1.7 to 10.4) |
| Acute myeloid leukemia | 2 | 0.090 | 22.3 (5.6 to 89.1) | 1.3 (0.3 to 5.2) |
| Other glial | 1 | 0.088 | 11.3 (1.6 to 80.3) | 0.6 (0 to 4.6) |
| Breast | 1 | 0.109 | 9.1 (1.3 to 65.7) | 0.6 (0 to 4.6) |
| Non-Hodgkin lymphoma | 1 | 0.232 | 4.3 (0.6 to 30.6) | 0.5 (−0.1 to 4.5) |
| Small intestine and colorectal | 1 | 0.094 | 10.6 (1.5 to 75.3) | 0.6 (0.0 to 4.6) |
| Other cancersa | 6 | 0.559 | 10.7 (4.8 to 23.9) | 3.6 (1.4 to 8.4) |
Other cancers include Pseudosarcomatous carcinoma; sebaceous adenocarcinoma of the skin; eccrine adenocarcinoma; precursor T-cell lymphoblastic lymphoma. CI = confidence interval.
Standardized incidence ratio (SIR) (95% CI) and excess absolute risk (EAR) (95% CI) for subsequent malignant neoplasms (SMN) at 25 years after primary cancer diagnosis
| . | Observed . | Expected . | SIR (95% CI) . | EAR (95% CI) per 10 000 person-years . |
|---|---|---|---|---|
| All SMNs | 28 | 3.451 | 8.1 (5.4 to 12.1) | 16.1 (10.0 to 25.0) |
| Sex | ||||
| Male | 13 | 1.559 | 8.3 (4.9 to 14.3) | 15.3 (8.1 to 27.7) |
| Female | 15 | 1.892 | 7.9 (4.4 to 14.2) | 16.8 (8.3 to 31.8) |
| Risk | ||||
| Low risk | 2 | 1.552 | 1.3 (0.2 to 9.1) | 0.7 (−1.9 to 18.7) |
| Intermediate risk | 3 | 0.815 | 3.7 (1.2 to 11.3) | 5.4 (0.4 to 20.9) |
| High risk | 22 | 0.787 | 28.0 (18.5 to 42.3) | 64.7 (42 to 99.0) |
| Age at diagnosis | ||||
| <1 | 3 | 1.430 | 2.1 (0.7 to 6.5) | 2.1 (−0.6 to 10.4) |
| 1-4 | 15 | 1.431 | 10.5 (6.2 to 17.8) | 21.3 (11.6 to 37.6) |
| 5-9 | 7 | 0.366 | 19.1 (8.5 to 43.2) | 62.1 (25.6 to 144.6) |
| ≥10 | 3 | 0.224 | 13.4 (3.6 to 50.3) | 87.7 (18.2 to 347.9) |
| SMN subtype | ||||
| Thyroid | 9 | 0.437 | 20.6 (9.5 to 44.5) | 5.6 (2.4 to 12.4) |
| Sarcoma | 7 | 0.367 | 19.1 (8.3 to 44.1) | 4.3 (1.7 to 10.4) |
| Acute myeloid leukemia | 2 | 0.090 | 22.3 (5.6 to 89.1) | 1.3 (0.3 to 5.2) |
| Other glial | 1 | 0.088 | 11.3 (1.6 to 80.3) | 0.6 (0 to 4.6) |
| Breast | 1 | 0.109 | 9.1 (1.3 to 65.7) | 0.6 (0 to 4.6) |
| Non-Hodgkin lymphoma | 1 | 0.232 | 4.3 (0.6 to 30.6) | 0.5 (−0.1 to 4.5) |
| Small intestine and colorectal | 1 | 0.094 | 10.6 (1.5 to 75.3) | 0.6 (0.0 to 4.6) |
| Other cancersa | 6 | 0.559 | 10.7 (4.8 to 23.9) | 3.6 (1.4 to 8.4) |
| . | Observed . | Expected . | SIR (95% CI) . | EAR (95% CI) per 10 000 person-years . |
|---|---|---|---|---|
| All SMNs | 28 | 3.451 | 8.1 (5.4 to 12.1) | 16.1 (10.0 to 25.0) |
| Sex | ||||
| Male | 13 | 1.559 | 8.3 (4.9 to 14.3) | 15.3 (8.1 to 27.7) |
| Female | 15 | 1.892 | 7.9 (4.4 to 14.2) | 16.8 (8.3 to 31.8) |
| Risk | ||||
| Low risk | 2 | 1.552 | 1.3 (0.2 to 9.1) | 0.7 (−1.9 to 18.7) |
| Intermediate risk | 3 | 0.815 | 3.7 (1.2 to 11.3) | 5.4 (0.4 to 20.9) |
| High risk | 22 | 0.787 | 28.0 (18.5 to 42.3) | 64.7 (42 to 99.0) |
| Age at diagnosis | ||||
| <1 | 3 | 1.430 | 2.1 (0.7 to 6.5) | 2.1 (−0.6 to 10.4) |
| 1-4 | 15 | 1.431 | 10.5 (6.2 to 17.8) | 21.3 (11.6 to 37.6) |
| 5-9 | 7 | 0.366 | 19.1 (8.5 to 43.2) | 62.1 (25.6 to 144.6) |
| ≥10 | 3 | 0.224 | 13.4 (3.6 to 50.3) | 87.7 (18.2 to 347.9) |
| SMN subtype | ||||
| Thyroid | 9 | 0.437 | 20.6 (9.5 to 44.5) | 5.6 (2.4 to 12.4) |
| Sarcoma | 7 | 0.367 | 19.1 (8.3 to 44.1) | 4.3 (1.7 to 10.4) |
| Acute myeloid leukemia | 2 | 0.090 | 22.3 (5.6 to 89.1) | 1.3 (0.3 to 5.2) |
| Other glial | 1 | 0.088 | 11.3 (1.6 to 80.3) | 0.6 (0 to 4.6) |
| Breast | 1 | 0.109 | 9.1 (1.3 to 65.7) | 0.6 (0 to 4.6) |
| Non-Hodgkin lymphoma | 1 | 0.232 | 4.3 (0.6 to 30.6) | 0.5 (−0.1 to 4.5) |
| Small intestine and colorectal | 1 | 0.094 | 10.6 (1.5 to 75.3) | 0.6 (0.0 to 4.6) |
| Other cancersa | 6 | 0.559 | 10.7 (4.8 to 23.9) | 3.6 (1.4 to 8.4) |
Other cancers include Pseudosarcomatous carcinoma; sebaceous adenocarcinoma of the skin; eccrine adenocarcinoma; precursor T-cell lymphoblastic lymphoma. CI = confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
